Background: Full audiological monitoring is the best strategy to detect hearing loss early and to provide timely intervention in the absence of a clinical method of otoprotection. Full monitoring requires audiological evaluation before, and then during and after ototoxic cancer treatment. In a worldwide context of monitoring protocols that vary substantially, we analyzed the audiological monitoring of childhood cancer patients over the last decade across treatment centers in
INTRODUCTION
Platinum chemotherapy or/and cranial radiation can be toxic to the ear, a property called ototoxicity. [1] [2] [3] Platinum can cause sensorineural hearing loss due to toxic levels of reactive oxygen species in the cochlea that damage hair cells, the stria vascularis, and spiral ganglion cells. 1 Radiation ≥30 Gray (Gy) can cause sensorineural or conductive hearing loss due to direct damage to the external ear canal, the cochlea, the brainstem, or small vessels of the inner ear. 1 High-frequency hearing loss is most common and may progress unnoticed until communication problems become apparent. 1, 4 In children, moderate or even rather minimal hearing loss can impair speech development, cause learning problems, or reduce quality of life. [5] [6] [7] [8] [9] It is, therefore, crucial that hearing loss is detected early. Clinicians might have the option to discuss whether cancer treatment can be modified, they can counsel patients and parents, offer hearing aids, and thus mitigate the downstream effects of hearing loss.
International guidelines [10] [11] [12] [13] [14] and clinical studies (Supplementary Table S1 ) recommend audiological monitoring because no clinical method of otoprotection yet exists. 15 Both the number of audiological evaluations (AE) recommended and their timing vary substantially.
However, all agree that full monitoring includes an initial AE at baseline, before ototoxic treatment, to exclude any preexisting hearing disorder; that evaluations should be repeated throughout the ototoxic treatment so that clinicians may modify cancer treatment; and that evaluation should continue after completion of cancer treatment to detect potential late-manifesting hearing loss. Patients receiving only cranial radiation should be evaluated both before and after radiation of ≥30 Gy. However, no study has yet investigated whether clinicians adhere to these recommendations, and whether patient characteristics or cancer treatment predict monitoring, or if participation in a clinical study plays a role in monitoring.
We characterized audiological monitoring in a national, registrybased sample of childhood cancer patients who received ototoxic cancer treatment. We analyzed predictors of audiological monitoring and evaluated whether audiological monitoring improved over the last decade.
METHODS

Study population
The Swiss Childhood Cancer Registry (SCCR) is a nationwide, population-based registry that includes all children and adolescents residing in Switzerland who have been diagnosed with leukemia, lymphoma, central nervous system (CNS) tumors, malignant solid tumors, or Langerhans cell histiocytosis prior to the age of 21. 16 Recent estimates indicate that the SCCR includes 91% of all patients diagnosed with cancer before the age of 16 in the years since 1985, and about 95% of those diagnosed since 1995. 17 The SCCR registers information on the diagnosis and treatment of the cancer and personal information.
Tumors are classified according to the International Classification of Childhood Cancer, third edition (ICCC-3). 18 Ethics approval of analyses of SCCR data is granted by the Ethics Committee of the Canton of Bern to the SCCR (KEK-BE: 166/2014).
Inclusion criteria
We included all patients registered in the SCCR who were treated with ototoxic cancer treatment in the nine Swiss Pediatric Oncology Centers ( Supplementary Fig. S1 ). We restricted the years of diagnosis to 2005-2013 because medical records from patients treated before 2005 are difficult to access due to Swiss data protection rules, 19 and the treatment and follow-up of patients diagnosed after 2013 was not finished when data collection ended in December 2015. We assumed that audiological monitoring may not have been the first priority in treating terminally ill children, and excluded the records of children who were not alive at the time of study; in any event, their medical records were often not available. 19 We defined ototoxic cancer treatment as platinum chemotherapy or cranial radiation ≥30 Gy according to the literature. 11, 13, 14, 20, 21 To determine whether patients fulfilled the inclusion criteria, we obtained their personal and treatment-related information from the SCCR.
Chart review
We reviewed the medical records retrospectively. We collected AEs, the corresponding audiologists' reports, oncological discharge reports, and cancer treatment protocols in all nine Swiss Pediatric Oncology Centers and the corresponding ear-nose-throat departments.
Audiological monitoring
Through the end of 2015, we collected all AEs that were performed as part of care before, during, and after cancer treatment, and recorded the type and timing of evaluation. We categorized type of AE as pure tone audiometry, extended high frequency audiometry, free field audiometry, auditory brainstem response, otoacoustic emissions (OAE) testing, speech audiometry, or tympanometry. To assess the timing of AE, we categorized tests as before, during, and after treatment.
We divided the extent of audiological monitoring into two categories:
(1) full audiological monitoring included patients with at least one AE at all stages (before, during, and after cancer treatment) and (2) minimal audiological monitoring included patients with one or more AE that occurred only after treatment. Patients with cranial radiation were defined as having had full audiological monitoring if they received at least one AE pre-and posttreatment. We graded the most recent AE for each ear separately and for frequencies up to 8 kHz according to the International Society of Pediatric Oncology (SIOP) Boston
Ototoxicity Scale, which is more sensitive to detect hearing loss than other ototoxicity scales. 22, 23 We defined hearing loss as ≥grade 1 (>20 dB above 4 kHz) according to the SIOP Boston Ototoxicity scale in the most affected ear, and graded severity from 0 to 4. 22
Cancer treatment information
We collected detailed patient information on cancer treatment from the SCCR, or from the clinic archives when it was not available in the SCCR. We recorded the name and arm of the clinical study, if 
Statistical analysis
We first determined how many children had had at least one AE overall, and at least one AE before, during, or after cancer treatment.
To investigate whether audiological monitoring varies between subgroups, we stratified for age at cancer diagnosis, ototoxic cancer treatment, clinical study participation, and hearing status at the last AE.
We then characterized the types of AEs used before, during, and after treatment, overall and stratified for age at cancer diagnosis. In a third step, we determined the number of AEs patients had among those who received any monitoring, and described the length of audiological follow-up after ototoxic cancer treatment. We only considered patients with ≥5 years between last ototoxic treatment and time of study to have similar chances to be monitored among patients. The fourth step assessed predictors of audiological monitoring by using logistic regression models. We first compared patients who had full audiological monitoring to all who did not have full audiological monitoring, and then compared patients who had minimal audiological monitoring to those without any audiological monitoring. We used gender, age at cancer diagnosis, ototoxic cancer treatment, and clinical study participation as independent variables. Finally, we assessed time trends in audiological monitoring. We compared proportions of children who received audiological monitoring before, during, and after treatment between periods of cancer diagnosis, and tested for trends.
To treat posttreatment differences with different lengths of followup equally, we considered only AEs within the first year after ototoxic treatment. We also used the Kaplan-Meier method to estimate cumulative incidence curves and calculated cumulative incidence for audiological monitoring 12 months after treatment stratified by period of diagnosis.
We used Stata (Version 13, Stata Corporation, Austin, TX) for all analyses. 
RESULTS
Characteristics of study population
TA B L E 2 Proportion of patients with audiological monitoring before, during, and after ototoxic cancer treatment
Before treatment (n = 185) During treatment a (n = 169) After treatment (n = 185) Officially included in a clinical study (n = 93) 25 (27) 68 (73) 15 (18) 70 (82) 23 (25) 70 (75) Treated according to a clinical study (n = 75) 27 (36) 48 (64) 18 (26) 52 (74) 15 (20) 60 (80) Treated not according to a clinical study (n = 17) 11 (65) 6 (35) 11 (79) 3 (21) 13 (76) 4 (24) Hearing loss at most recent AE c 0.622 0.108 0.402
No (n = 115) 35 (30) 80 (70) 26 (25) 80 (75) 27 (23) 88 (77) Yes (n = 56) 15 (27) 41 (73) 7 (13) 45 (87) 10 (18) 46 (82) a Only 169 patients, those treated with platinum, could have had audiological monitoring during treatment because monitoring is not conducted during treatment with cranial radiation. b Includes seven patients who received both cisplatin and carboplatin. c Hearing outcome was not available for 14 patients.
with larger clinics and assessment of the complete medical records for a patient was not feasible. This resulted in 185 patients whose records
were available for analysis ( Supplementary Fig. S1 , Table 1 ). The mean age (SD) of these patients was 7 (5) years at diagnosis and 11 (6) years at the most recent AE. Table 1 gives details on clinical characteristics and cancer treatment of the study population. Fifty-six patients (30%) had a pathological result in the most recent AE, among whom 25 patients (13%) had severity grade 1, while 21 patients (11%) had grade 2, seven patients (4%) had grade 3, and three patients (2%) had grade 4.
Proportion tested and type of AEs
Overall, 175 children (95%) treated with ototoxic cancer treatment had at least one AE, but only 78 children (42%) had full audiological monitoring in all phases of cancer treatment. Looking at each phase separately, 122 patients (66%) had at least one AE before treatment,
125 (74%) were tested at least once during treatment, and 134 (72%)
were tested one or more times after treatment (Table 2 ). Evaluation before treatment was more common in patients who were included in a clinical study or were treated according to a study protocol than in those whose treatment was not part of or conducted according to a study (73% and 64%, respectively, vs. 35%). Evaluation during treatment was less common in those younger than 5 years at diagnosis (60%), in those with carboplatin (61%), and in nonstudy patients (21%); and more common in patients older than 9 years at diagnosis (89%), in those with cisplatin (81%) or with both platinum chemotherapy and cranial radiation ≥30 Gy (77%), or in those officially included in a clinical study (82%). Evaluation after treatment was less common in patients with cranial radiation ≥30 Gy (56%), in those with carboplatin (51%), or in nonstudy patients (24%), but more common in those with cisplatin (85%) or both platinum chemotherapy and cranial radiation ≥30 Gy (81%).
Pure tone audiometry, extended high-frequency audiometry, and OAE testing were the most frequently used types of AEs, independent of the time of treatment (Supplementary Table S2 ).
Frequency of AEs and follow-up period
Patients had in median one AE before, three during, or two after treatment (Table 3) . During treatment, AEs were more frequent in patients with both platinum chemotherapy and cranial radiation ≥30 Gy (P < 0.001). After treatment, AEs were done more often in patients older than 9 years at diagnosis (P = 0.020), in study patients (P = 0.036) and in those who have developed hearing loss (P < 0.001).
Patients who received ototoxic cancer treatment 5 or more years ago had a median audiological follow-up of 29 months. The longest followup had those who received cranial radiation of ≥30 Gy (median 56 months, P = 0.013).
Predictors for full and minimal audiological monitoring
Full audiological monitoring differed with clinical study participation (Table 4) . Full monitoring was less common in nonstudy patients 
Time trends of audiological monitoring
Proportions of patients with audiological monitoring changed over the last decade (Fig. 1) . 
DISCUSSION
This study of Swiss childhood cancer patients found that less than half of the children had full audiological monitoring that included an AE before, during, and after ototoxic cancer treatment. Seventy-two percent of study patients did receive at least one AE after treatment, but nonstudy patients had significantly less audiological monitoring.
Though monitoring during and after ototoxic treatment has become more frequent over the last decade, monitoring before treatment has been and remains insufficient.
Evaluations before treatment provide a crucial reference for assessing hearing changes and are needed for ototoxicity grading Monitoring during treatment is specified by treatment protocols that have different monitoring schedules (Supplementary Table S1 ).
TA B L E 4 Predictors of audiological monitoring in childhood cancer patients
For example, the Euramos protocol for osteosarcoma treatment used in 31 children in our study population suggested that only an evaluation before the third and fourth cycle of cisplatin is needed. But, for 31 children treated according to HIT-2000, a protocol used to treat medulloblastoma, CNS PNET or ependymoma, monitoring was advised at each cycle of platinum chemotherapy or cranial radiation. The protocol used to treat 10 children with medulloblastoma, ACNS0331, specified monitoring prior to every cisplatin cycle, which is in line with both American Academy of Audiology (AAA) and American SpeechLanguage-Hearing Association (ASHA) recommendations. 10, 12 Overall, 74% of our patients had at least one AE during treatment. The percentage rose to 89% among patients who were older than 9 years, while 81% of those treated with cisplatin and 77% of those treated with both platinum chemotherapy and cranial radiation were tested at least once, as were 82% of those included in a clinical study.
After ototoxic treatment, the St. Jude Children´s research hospital protocol recommends yearly evaluation up to 10 years after cancer treatment (Supplementary Table S1 ). 30 However, the Children's 22 In all cases, though, audiological monitoring for several years after cancer treatment is important as hearing loss may only appear many years later particularly for patients treated with cranial radiation. 3, 33 Guidelines for audiological monitoring have changed over time.
The 1994 ASHA guideline reported ototoxic effects only for platinum chemotherapy; audiological effects of cranial radiation were not well known at that time. 10, 34 Fifteen years later, the AAA guideline recommended annual monitoring for 1 to 2 years after cranial radiation. 12 Independent of monitoring schedules, evaluations themselves may be adjusted by, for example, focusing on the high frequencies that are critical in determining the onset of hearing loss. 24 In the current St.
Jude Children's Hospital ototoxicity protocol, the number of evaluations depends on the platinum compound used or the dose of cranial radiation, but at least 11 hearing tests are recommended. 30 It is there- In summary, our study indicates that audiological monitoring guidelines are insufficiently followed in Switzerland, particularly when patients are neither participants in a study nor treated according to a specific study protocol. We need to increase clinicians' knowledge of the importance of full audiological monitoring before, during, and after cancer treatment to increase compliance with international monitoring guidelines. Pediatric oncologists should be made aware of the need to send childhood cancer patients who will receive potentially ototoxic treatment to an audiologist for pretreatment monitoring. Standardized audiological monitoring that begins with a baseline evaluation is essential for the best possible audiological outcomes.
